Low-dose cholesterol medicines versus high-dose after heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This study compares two cholesterol treatment approaches after a heart attack: a lower dose combination versus a higher dose single medicine. It aims to see which option works well and is tolerable for people after a treated heart attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult age 19 or older
- Have had a heart attack (either type) that was treated with a procedure to open blocked heart arteries (percutaneous coronary intervention)
- Agree to sign the study consent form
- If you can get pregnant: you must use effective birth control and have a required pregnancy test
- You must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.
This trial compares two cholesterol-lowering treatment plans after a heart procedure where new drug-eluting stents were placed: a combination of high-intensity statin plus ezetimibe versus high-intensity statin alone. It may help find which option lowers cholesterol more effectively and safely over the first year after the procedure.
This study tests whether a newer cholesterol-lowering injection, given early after a heart attack, helps keep the plaque in your arteries stable and reduces future risk. It compares the new medicine added to your usual statin treatment.
This trial tests whether ezetimibe, a cholesterol-lowering drug, changes the bacteria in your gut. It may help people with heart disease or high cholesterol who are already on a statin.
This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.
This study compares two different ways of lowering cholesterol: a moderate statin (pitavastatin) plus another drug (ezetimibe) versus a stronger statin alone. The goal is to see which approach is safer regarding the risk of developing new diabetes.
Hear when a new Statin Adverse Reaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.